Free shipping on all orders over $ 500

BI-847325

Cat. No. M5236

All AbMole products are for research use only, cannot be used for human consumption.

BI-847325 Structure
Size Price Availability Quantity
5mg USD 125 In stock
10mg USD 210 In stock
25mg USD 415 In stock
50mg USD 680 In stock
100mg USD 930 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

In vitro: BI-847325 shows growth-inhibitory effects on BRAF-mutant and vemurafenib-resistant melanoma cells with IC50 ranging from 0.3 nM to 2 μM, and prevents colony formation in six BRAF-mutant melanoma cell lines. BI-847325 also induces apoptosis by reducing Mcl-1 expression. In vivo: In mice bearing 1205Lu and 1205LuR xenografts, BI-847325 (75 mg/kg, p.o.) causes significant tumor suppression without significant alteration in the body weights.

Protocol (for reference only)
Cell Experiment
Cell lines M229, M229R, A375, A375R, WM793, WM793R, 1205Lu, 1205LuR, M249, M249R, WM164, WM164R, WM39 and RPMI17951 cells
Preparation method Cells are plated at a density of 2.5 × 10^3 cells per 100 μL and left to grow overnight before being treated with increasing concentrations of BI-847325 for 72 hours. The metabolic activity is determined using Alamar blue reagent as per the manufacturer's protocol.
Concentrations 30 μM
Incubation time 72 h
Animal Experiment
Animal models Mice bearing 1205Lu and 1205LuR xenografts
Formulation 2-hydroxyethyl cellulose, polysorbate 80 with pH adjusted to 2.8 with 1 M HCl
Dosages 70 mg/kg
Administration p.o.
Chemical Information
Molecular Weight 464.56
Formula C29H28N4O2
CAS Number 1207293-36-4
Solubility (25°C) 19 mg/mL warmed in DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Sini P, et al. Mol Cancer Ther. Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases.

[2] Phadke MS, et al. Mol Cancer Ther. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.

Related MEK Products
AS703026

Pimasertib (AS-703026) is a novel selective MEK1/2 inhibitor, and induces pleiotropic anti-myeloma activity in vitro and in vivo.

AZD6244

AZD6244 (ARRY-142886, Selumetinib) is a potent MEK 1/2 inhibitor with GI50 values ranging from 14 to 50 nM.

AZD8330

AZD8330 (ARRY-424704) is a novel, selective, highly efficacious, uncompetitive MEK inhibitor with an IC50 of 7 nM.

CI-1040

CI-1040 (PD184352) is a targeted signal transduction inhibitor of MEK with a ki value of 300nM in vitro.

ARRY-162 (Binimetinib)

ARRY-162 (MEK-162; Binimetinib) is a selective, potent inhibitor of MEK and cellular pERK with IC50 of 12 nM and 11 nM, respectively.

  Catalog
Abmole Inhibitor Catalog




Keywords: BI-847325 supplier, MEK, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.